AI tool boosts imperfect antibiotic candidates, with 85% working in lab tests

Researchers at the University of Pennsylvania have developed ApexGO, a novel, AI-powered method for turning promising but imperfect antibiotic candidates into more potent ones. The science-journalism coverage adds useful context, while the strongest evidential footing still comes from the underlying data, papers or institutional documentation.

It matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. Unlike many existing AI approaches to antibiotic discovery, which screen large databases for molecules that might work, ApexGO starts with a small number of imperfect candidates. This article has been reviewed according to Science X's editorial process and policies.

Editors have highlighted the following attributes while ensuring the content's credibility: Add as preferred source A 3D-printed example of the kind of antibiotic peptide the. ApexGO gives us a way to navigate that space with far more direction," says César de la Fuente, Presidential Associate Professor in Bioengineering and in Chemical and Biomolecular.

He is co-senior author of a new paper describing the method in Nature Machine Intelligence. Gardner, Assistant Professor in Computer and Information Science (CIS) and the paper's other senior co-author.

Instead, the majority of the molecules it designed actually worked. " For years, the de la Fuente lab has looked for antibiotic candidates in unlikely places, from frog secretions. APEX helped us find promising antibiotic candidates in enormous biological datasets," says Marcelo Torres, Research Assistant Professor of Psychiatry in the Perelman School of.

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

It would be impossible to test every possible peptide," says Yimeng Zeng, a doctoral student in CIS and co-first author of the paper. But it can also move into less certain regions, where there may still be hidden improvements.

Because this item comes through Phys. org Biology as science journalism, it should be treated as contextual reporting rather than primary evidence. Good science reporting can identify why a result matters, connect it to the wider literature and make technical work readable, but the decisive evidence remains in the original paper, dataset, mission release or technical record. That distinction is especially important when a story is later repeated by aggregators, because repetition increases visibility, not evidential strength.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source